Updated 02:01 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,876.40 -0.25% CL 88.33 -0.26% BTC 64,613.34 +0.76%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,876 −0.25% BTC $64,613 +0.76% VIX 19.30 +3.21% latest tape · as of 02:01 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic

Kamada Ltd. logoKamada Ltd.

KMDA · Nasdaq · USD · Market cap $445M · 462 employees

Kamada Ltd.

PASS · Titan Ethical · score 70.0
8.09 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price8.09 USD at the 13 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenPasses, score 70.0 out of 100
  • OptionsOpen interest leans heavily to calls (put/call 0.65)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $9.90 to $15.86, base estimate $13.34 (screen dated 2026-11-13).

Current read
Markup ?
Undervalued · screened 2026-11-13
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.65, read 2026-11-15
  • Ethical passes the values gate
Price8.09 USD
Fair value13.34
Ethical score70.0/100
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-15Read Markup8.09+0.0% to today ✓Distribution gives way to Markup after a 12% rise in 7 days
2026-11-08Read Distribution7.23+11.9% to today Markdown gives way to Distribution after an 8% slide in 3 weeks
2026-10-18Read Markdown7.83+3.3% to today Distribution gives way to Markdown after an 11% slide in 7 days
2026-10-11Read Distribution8.83-8.4% to today ✓Markup gives way to Distribution after a 12% rise in 5 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Kamada Ltd. holds its Markup at $8.09. Elevated stress, defensive posture warranted, held for 36 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateElevated stress, defensive posture warranted, held for 36 days
Price at the screen$8.09
Valuation20.29 trailing · 13.37 forward price to earnings
Values screenPASS · score 70.0
Beta0.20
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 2.54% Below 33% Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 16.61% Below 33% Cash held in interest-bearing accounts and securities is 16.6% of assets, under the one-third limit. Pass
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass
Revenue purity 1.06% Below 5% Only 1.1% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Kamada clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when KMDA's ethical verdict changes

Today KMDA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 39% discount to our $13.34 fair value, weak competitive moat, 22.70% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

9.90Conservative13.34Base case15.86Growth case 8.09Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 39.4% discount to the base estimate.

The Street's Range
11.00Street low 14.00Street average 15.00Street high 8.09Price

Third-party analyst targets: 4 covering, consensus Strong Buy. The average target sits +73% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $13.34, with a range of $9.90 to $15.86, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it stands out

A 23%-growth business trading at just 13.4x forward earnings, with a weak competitive moat. That is a 39% discount to our $13.34 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 4 analysts rate it Strong Buy with a $14.00 average target, about 73% above the screened price.

The fundamentals · plain-English read
Forward P/E13.4xcheap for a company growing this fast
Trailing P/E20.3xa premium valuation
EPS, trailing0.38
EPS, forward0.58
Revenue growth+22.7%strong top-line growth
Profit margin11.6%thin but positive margins
Return on equity8.4%a modest return on shareholder capital
FCF yield3.48%
Dividend yield3.19%
Debt to equity4.38heavy leverage: higher risk if revenue softens
Current ratio4.06comfortably covers its short-term bills
Beta0.20barely tracks the market's swings
Short interest, float0.01%
52-week range6.60 - 9.35
MoatWEAK
Market cap$445M
Employees462

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

KMDA trades on Nasdaq (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-15 Markup · changed $8.09 +11.9% Entry 12

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-11-08 Distribution · changed $7.23 -6.1% Entry 11

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-11-01 Markdown $7.70 -1.7% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-10-25 Markdown $7.83 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-10-18 Markdown · changed $7.83 -11.3% Entry 8

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-10-11 Distribution · changed $8.83 +0.0% Entry 7

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-10-02 Markup $8.83 +11.9% Entry 6

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-09-03 Markup · changed $7.89 +11.9% Entry 5

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-08-03 Markdown · changed $7.05 -5.2% Entry 4

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

2026-07-18 Distribution $7.44 +0.0% Entry 3

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it strong buy, with a mean price target of $13.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on KMDA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in KMDA's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $8.45 -14.5% · $855 -14.5%
2 months $8.49 -14.9% · $851 -14.9%
3 months $8.43 -14.3% $0.25 $886 -11.4%
6 months $6.81 +6.0% $0.25 $1,097 +9.7%
1 year $6.78 +6.5% $0.25 $1,102 +10.2%
2 years $4.95 +45.8% $0.45 $1,549 +54.9%
3 years $5.03 +43.7% $0.45 $1,526 +52.6%
5 years $5.57 +29.8% $0.45 $1,379 +37.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever KMDA does next, these words stay.

Kamada Ltd. · KMDA · Markup · $8.09
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.